Follow the BridgeBio Oncology Therapeutics, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Market capitalisation: €722.6m. The latest transaction was disclosed on 6 July 2026 (J). Among the most active insiders: Chen Bihua. All data is openly available.
12
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
30Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
BridgeBio Oncology Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for patients with cancer. It specializes in targeted therapies and genetics-based approaches.